Teva Pharmaceutical Industries Ltd. Press Releases https://ir.tevapharm.com/generated by Q4Mon, 18 May 2026 08:30:51 -0400Copyright Q4 Inc. All rights reserved.Fitch Upgrades Teva to Investment Grade Amid Pivot to Growth Executione9c02e72-42f9-41a5-895d-2bd51d655786https://ir.tevapharm.com/news-and-events/press-releases/press-release-details/2026/Fitch-Upgrades-Teva-to-Investment-Grade-Amid-Pivot-to-Growth-Execution/default.aspxMon, 18 May 2026 08:30:00 -0400Teva Study Finds Only 23% of Younger Adults with Mood Disorders and Tardive Dyskinesia (TD) Symptoms Are Formally Diagnosed with TD Despite Widespread Impact08f46be2-e3ff-41cc-868c-87cbcff12142https://ir.tevapharm.com/news-and-events/press-releases/press-release-details/2026/Teva-Study-Finds-Only-23-of-Younger-Adults-with-Mood-Disorders-and-Tardive-Dyskinesia-TD-Symptoms-Are-Formally-Diagnosed-with-TD-Despite-Widespread-Impact/default.aspxMon, 18 May 2026 08:00:00 -0400Teva to Present at the BofA Securities Health Care Conference9bbfcd80-c7c0-4ffe-8fab-07ee499ab9e1https://ir.tevapharm.com/news-and-events/press-releases/press-release-details/2026/Teva-to-Present-at-the-BofA-Securities-Health-Care-Conference/default.aspxMon, 04 May 2026 16:30:00 -0400Teva’s 2025 Healthy Future Report Highlights Environmental and Access to Medicines Progress, Including Meeting All Sustainability-Linked Bond Targetsee54a1ee-2c41-4aad-b98f-cc6ef4ea86f1https://ir.tevapharm.com/news-and-events/press-releases/press-release-details/2026/Tevas-2025-Healthy-Future-Report-Highlights-Environmental-and-Access-to-Medicines-Progress-Including-Meeting-All-Sustainability-Linked-Bond-Targets/default.aspxThu, 30 Apr 2026 08:30:00 -0400Teva Delivers Strong Q1 2026 Results Driven by Innovative Portfolio Growth and Disciplined Execution7bcedf05-43dd-427a-91d6-63c0e05c4fe1https://ir.tevapharm.com/news-and-events/press-releases/press-release-details/2026/Teva-Delivers-Strong-Q1-2026-Results-Driven-by-Innovative-Portfolio-Growth-and-Disciplined-Execution/default.aspxWed, 29 Apr 2026 07:00:00 -0400Teva to Acquire Emalex Biosciences, Adding NDA-Ready, First-in-Class Therapy to Neuroscience Pipeline and Accelerating Teva’s Pivot to Growth Strategy6fddd6ad-aa0b-46e7-9703-66e55f2700e6https://ir.tevapharm.com/news-and-events/press-releases/press-release-details/2026/Teva-to-AcquireEmalexBiosciences-Adding-NDA-Ready-First-in-Class-Therapy-to-Neuroscience-Pipeline-and-Accelerating-Tevas-Pivot-to-Growth-Strategy/default.aspxWed, 29 Apr 2026 06:30:00 -0400Teva Launches Home Ground™ Schizophrenia Community, a New Online Resource Hub for People Living with Schizophrenia and Their Care Partners14b5286a-aed1-4103-9a18-41f494b83e64https://ir.tevapharm.com/news-and-events/press-releases/press-release-details/2026/Teva-Launches-Home-Ground-Schizophrenia-Community-a-New-Online-Resource-Hub-for-People-Living-with-Schizophrenia-and-Their-Care-Partners/default.aspxWed, 15 Apr 2026 08:00:00 -0400Community Routes: Access to Mental Health Care Provides Continued Funding for Mental Health Services at Free & Charitable Clinics19fb52bf-edea-4c77-9471-bb9b3a6dadc2https://ir.tevapharm.com/news-and-events/press-releases/press-release-details/2026/Community-Routes-Access-to-Mental-Health-Care-Provides-Continued-Funding-for-Mental-Health-Services-at-Free--Charitable-Clinics/default.aspxTue, 14 Apr 2026 08:00:00 -0400Teva Gains Biosimilar Momentum with U.S. FDA Approval of PONLIMSI™ (denosumab-adet) and Dual Filing Acceptance for Biosimilar Candidate to Xolair® (omalizumab)8a5067d9-0ad3-4c75-8964-08ac64fd6608https://ir.tevapharm.com/news-and-events/press-releases/press-release-details/2026/Teva-Gains-Biosimilar-Momentum-with-U-S--FDA-Approval-of-PONLIMSI-denosumab-adet-and-Dual-Filing-Acceptance-for-Biosimilar-Candidate-to-Xolair-omalizumab/default.aspxMon, 30 Mar 2026 08:00:00 -0400Teva Releases Q1 2026 Aide Memoire42773011-a6c3-4e53-a3d8-e30e38d9ed03https://ir.tevapharm.com/news-and-events/press-releases/press-release-details/2026/Teva-Releases-Q1-2026-Aide-Memoire/default.aspxThu, 19 Mar 2026 16:30:00 -0400